Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
Withdrawn before enrolling · Phase 2
Conditions studied: Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder
In brief
RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders. Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus. Phenylbutyrate may make cells infected with Epstein-Barr virus more sensitive to valganciclovir. Giving phenylbutyrate together with valganciclovir may block the growth of Epstein-Barr virus-infected cells and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving phenylbutyrate together with valganciclovir works in treating patients with relapsed or refractory Epstein-Barr virus-positive cancer.
Key facts
- Study ID
- NCT00387530
- Run by
- University of California, San Diego
- People needed
- 0
- Starts
- 2006-05-01
- Expected to finish
- 2008-01-01
- Last updated by the study team
- 2019-08-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Rebecca and John Moores UCSD Cancer Center — La Jolla, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.